Tags

Type your tag names separated by a space and hit enter

affron[®] a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial.
Complement Ther Med. 2017 Aug; 33:58-64.CT

Abstract

BACKGROUND

In recent years phytotherapy has been explored as a source for alternative treatments for mood disorders. One potential candidate is saffron (Crocus sativus L.), whose main bioactive components are crocins and safranal.

OBJECTIVES

The aim of this study was to investigate the efficacy of affron[®], a standardised stigmas extract from Crocus sativus L. for improving mood, stress, anxiety and sleep quality in healthy adults.

METHODS

In this 3 arm study, 128 participants self-reporting low mood but not diagnosed with depression, were given affron[®] at 28mg/day, 22mg/day, or a placebo treatment in a randomized, double-blind, placebo-controlled trial for 4 weeks. Mood was measured at baseline and at the end of the study, using the POMS (primary outcome measure) and PANAS questionnaires, and the DASS-21 scale. Sleep was monitored using Sleep Quality Index (PSQI).

RESULTS

Analysis indicated a significant decrease in negative mood and symptoms related to stress and anxiety at a 28mg/day dose (with a significant difference between 28mg/day and placebo on the POMS Total Mood Disturbance scale, p<0.001, d=-1.10), but no treatment effect at the 22mg/day dose.

LIMITATIONS

The main weaknesses of this investigation were found in the self-reporting nature of both the screening and the testing.

CONCLUSIONS

affron[®] increased mood, reduced anxiety and managed stress without side effects, offering a natural alternative to standard treatments.

Authors+Show Affiliations

University of Southern Queensland, School of Psychology and Counselling, Toowoomba, Australia.RDC Clinical, Brisbane, Australia. Electronic address: amanda@rdcglobal.com.au.University of Southern Queensland, School of Psychology and Counselling, Toowoomba, Australia.Institute of Food, Brain and Behaviour, Oxford, UK.Pharmactive Biotech Products S.L. Parque Científico de Madrid, Madrid, Spain.Instituto de Investigación en Ciencias de la Alimentación CIAL (CEI CSIC-UAM), C/Nicolás Cabrera, 9, E-28049 Madrid, Spain.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

28735826

Citation

Kell, Graham, et al. "Affron[®] a Novel Saffron Extract (Crocus Sativus L.) Improves Mood in Healthy Adults Over 4 Weeks in a Double-blind, Parallel, Randomized, Placebo-controlled Clinical Trial." Complementary Therapies in Medicine, vol. 33, 2017, pp. 58-64.
Kell G, Rao A, Beccaria G, et al. Affron[®] a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;33:58-64.
Kell, G., Rao, A., Beccaria, G., Clayton, P., Inarejos-García, A. M., & Prodanov, M. (2017). Affron[®] a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complementary Therapies in Medicine, 33, 58-64. https://doi.org/10.1016/j.ctim.2017.06.001
Kell G, et al. Affron[®] a Novel Saffron Extract (Crocus Sativus L.) Improves Mood in Healthy Adults Over 4 Weeks in a Double-blind, Parallel, Randomized, Placebo-controlled Clinical Trial. Complement Ther Med. 2017;33:58-64. PubMed PMID: 28735826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - affron[®] a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. AU - Kell,Graham, AU - Rao,Amanda, AU - Beccaria,Gavin, AU - Clayton,Paul, AU - Inarejos-García,Antonio Manuel, AU - Prodanov,Marin, Y1 - 2017/06/13/ PY - 2017/02/03/received PY - 2017/04/15/revised PY - 2017/06/04/accepted PY - 2017/7/25/entrez PY - 2017/7/25/pubmed PY - 2017/9/2/medline KW - Clinical trial KW - Depression KW - Mood disorders KW - Phytonutrient KW - Saffron extract SP - 58 EP - 64 JF - Complementary therapies in medicine JO - Complement Ther Med VL - 33 N2 - BACKGROUND: In recent years phytotherapy has been explored as a source for alternative treatments for mood disorders. One potential candidate is saffron (Crocus sativus L.), whose main bioactive components are crocins and safranal. OBJECTIVES: The aim of this study was to investigate the efficacy of affron[®], a standardised stigmas extract from Crocus sativus L. for improving mood, stress, anxiety and sleep quality in healthy adults. METHODS: In this 3 arm study, 128 participants self-reporting low mood but not diagnosed with depression, were given affron[®] at 28mg/day, 22mg/day, or a placebo treatment in a randomized, double-blind, placebo-controlled trial for 4 weeks. Mood was measured at baseline and at the end of the study, using the POMS (primary outcome measure) and PANAS questionnaires, and the DASS-21 scale. Sleep was monitored using Sleep Quality Index (PSQI). RESULTS: Analysis indicated a significant decrease in negative mood and symptoms related to stress and anxiety at a 28mg/day dose (with a significant difference between 28mg/day and placebo on the POMS Total Mood Disturbance scale, p<0.001, d=-1.10), but no treatment effect at the 22mg/day dose. LIMITATIONS: The main weaknesses of this investigation were found in the self-reporting nature of both the screening and the testing. CONCLUSIONS: affron[®] increased mood, reduced anxiety and managed stress without side effects, offering a natural alternative to standard treatments. SN - 1873-6963 UR - https://neuro.unboundmedicine.com/medline/citation/28735826/affron[®]_a_novel_saffron_extract__Crocus_sativus_L___improves_mood_in_healthy_adults_over_4_weeks_in_a_double_blind_parallel_randomized_placebo_controlled_clinical_trial_ DB - PRIME DP - Unbound Medicine ER -